TS-032588 — Engineered calmodulin-based therapeutics for the treatment of cardiovascular diseases.
While there are three ryanodine receptors responsible for the release of calcium from intracellular stores during excitation-contraction, ryanodine receptor channel 2 (RyR2) has emerged as an important target in the treatment of cardiac failure. When RyR2 channels cease to effectively regulate int…